Moffitt Cancer Center Cell Coast Conference 2025

• Target Audience: hematologists, oncologists, and cellular therapy practitioners
• Sample video: contact me for sample video
• Information:

1. Overview

The Moffitt Cancer Center Cell Coast Conference 2025 is a premier event dedicated to the latest breakthroughs in cellular cancer therapies. This course brings together leading experts to explore emerging targets, advanced engineering strategies, and next-generation modalities like CAR-T, bispecific antibodies, and TIL therapies, aiming to enhance treatment efficacy and patient care.

Join us for the 2nd Annual Cell Coast Conference, where leading experts, researchers, and industry pioneers will converge to explore the latest breakthroughs in cellular cancer therapy. This premier event will feature cutting-edge discussions on emerging targets, advanced engineering strategies, and next-generation therapeutic modalities, all aimed at enhancing the efficacy and delivery of cellular therapies.

Attendees will engage with top-tier experts and industry leaders through four dynamic session tracks:

Novel Targets and Approaches

Advanced Engineering and Modalities

Optimizing Delivery and Efficacy

Interactive Debates and Controversies

The 2nd Annual Cell Coast Conference provides an unparalleled opportunity to gain insights from world-renowned experts, participate in collaborative discussions, and network with peers driving innovation in the field. Whether you’re a researcher, clinician, or industry professional, this conference will equip you with the latest knowledge and strategies to accelerate the development of next-generation cellular therapies for cancer. Don’t miss this opportunity to be at the forefront of transformative cancer treatment advancements!

2. Learning Objectives

Evaluate the efficacy and toxicity management of bispecific antibody therapies for Non-Hodgkin Lymphoma and Multiple Myeloma.

Analyze updates in CAR-T cell therapies for ALL, solid tumors, and autoimmune diseases, including in-vivo and armored CAR-T strategies.

Discuss the operationalization of new therapies like Tarlatamab and the logistics of clinical care for cell therapy patients.

Compare CAR-T versus BiTEs for hematologic malignancies and assess biomarkers for toxicity and response.

3. Target Audience

Best for hematologists, oncologists, and cellular therapy practitioners who want updates on CAR-T, bispecific antibodies, and TIL therapies.

This conference is specifically crafted for professionals in the field, including cellular therapy practitioners, hematologists, community oncologists, pharmacists, advanced practice professionals, and dedicated oncology nurses.  Particular attention will be paid to the interface between referring providers and cellular therapists, including when and how to refer patients.

4. Topics

Bispecific Antibody Therapy in Non-Hodgkin Lymphoma and Toxicity Management

Operationalization of Tarlatamab Therapy at Moffitt Cancer Center

Bispecific Antibody Therapy for Relapsed Refractory Multiple Myeloma

Keynote Speaker Combination CAR T and anti-IFNG Strategies for the Management of Advanced Cancers

Novel Cellular Therapies for Sarcoma

CAR-T Cell Updates in ALL

GPC3 CAR T Cells for the Management of Advanced Cancers

CAR-T for Autoimmune Diseases

Biomarkers for Toxicity and Response in CAR-T for Multiple Myeloma

In-Vivo CAR-T

Claudin 18.2 for Gastrointestinal Malignancies

T Cell Fitness What’s Next after BCMA CAR

Armored CAR-T Strategies for Advanced Cancers

Allogeneic “off the shelf” IO approaches for MDS AML

CAR-NK Strategies for the Management of Advanced Cancers

Bladder Til Trial

Future of TIL Therapy

Novel TIL Therapies in Lung Cancer

CAR-T for Glioblastoma

GCC19 CAR T Trial

Practical Logistics of Clinical Care for Cell Therapy Patients

CAR-T vs BiTEs for Hematologic Malignancies (Part 1)

CAR-T vs BiTEs for Hematologic Malignancies (Part 2)